公开(公告)号：US20240239772A1

公开(公告)日：2024-07-18

申请号：US18556564

申请日：2022-04-21

申请人： The Cleveland Clinic Foundation

发明人： Shaun R. Stauffer ,  Sang Hoon Han ,  Alice Hooper ,  Joshua Maw ,  Dhiraj P. Sonawane ,  Matthew R. Porter ,  Steven Martinez ,  Joseph Alvarado ,  Jonathan D. Macdonald

IPC分类号： C07D403/12 ,  A61K31/4192 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/496 ,  A61P31/14 ,  C07D249/04 ,  C07D249/18 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

CPC分类号： C07D403/12 ,  A61K31/4192 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/496 ,  A61P31/14 ,  C07D249/04 ,  C07D249/18 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

摘要： Disclosed herein are compounds that inhibit 3C-like protease and inhibit replication of viruses, including SARS-CoV-2. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in a method of treating a viral infection, such as a coronavirus infection.

公开(公告)号：US20240238330A1

公开(公告)日：2024-07-18

申请号：US18419108

申请日：2024-01-22

申请人： Proteobioactives Pty Ltd

发明人： Peter Ghosh ,  Jack Edelman

IPC分类号： A61K31/737 ,  A61K9/00 ,  A61K9/48 ,  A61K31/196 ,  A61K31/365 ,  A61K31/415 ,  A61K31/42 ,  A61K31/444 ,  A61P19/02 ,  A61P29/00

CPC分类号： A61K31/737 ,  A61K9/0053 ,  A61K9/4816 ,  A61K31/196 ,  A61K31/365 ,  A61K31/415 ,  A61K31/42 ,  A61K31/444 ,  A61P19/02 ,  A61P29/00

摘要： Pharmaceutical and veterinary compositions for oral administration comprising a therapeutically effective amount of at least one coxib together with a therapeutically effective amount of pentosan polysulfate or a pharmaceutically acceptable salt thereof are described. The compositions have application for the prophylaxis or treatment of pain and/or inflammation. There is also described a pharmaceutical or vete1inal) composition comprising a therapeutically effective amount of at least one coxib. The compositions in at least some forms may be lactose free and/or provided in a non-gelatin capsule. Further, there are provided methods for administration of a therapeutically effective amount of at least one coxib in combination with pentosan polysulfate or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of pain and/or inflammation.

公开(公告)号：US20240238264A1

公开(公告)日：2024-07-18

申请号：US18406825

申请日：2024-01-08

申请人： Washington University ,  Disarm Therapeutics, Inc.

发明人： Jeffrey MILBRANDT ,  Kow ESSUMAN ,  Yo SASAKI ,  Aaron DIANTONIO ,  Xianrong MAO ,  Rajesh DEVRAJ ,  Raul Eduardo KRAUSS ,  Robert Owen HUGHES

IPC分类号： A61K31/4439 ,  A61K31/047 ,  A61K31/145 ,  A61K31/198 ,  A61K31/41 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/566 ,  A61K31/7048 ,  A61K31/7084 ,  A61K33/243 ,  A61K33/245 ,  A61K33/28 ,  A61K33/30 ,  A61K47/52 ,  A61K47/55 ,  A61P25/28

CPC分类号： A61K31/4439 ,  A61K31/047 ,  A61K31/145 ,  A61K31/198 ,  A61K31/41 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/566 ,  A61K31/7048 ,  A61K31/7084 ,  A61K33/243 ,  A61K33/245 ,  A61K33/28 ,  A61K33/30 ,  A61K47/52 ,  A61K47/55 ,  A61P25/28

摘要： The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

公开(公告)号：US20240228491A1

公开(公告)日：2024-07-11

申请号：US18557795

申请日：2022-04-28

申请人： SCINNOHUB PHARMACEUTICAL CO., LTD.

发明人： Anle YANG ,  Dewei ZHANG ,  Lijin DONG ,  Quanhong HE ,  Tao YI ,  Jiang MENG ,  Lin TIAN ,  Jie LIANG ,  Ze FENG ,  Kai HU ,  Xiaodong ZHANG ,  Yi ZHANG ,  Xi HU ,  Yanan HOU ,  Jun TANG

IPC分类号： C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00 ,  C07D519/00

摘要： Disclosed are a methionine adenosyltransferase inhibitor represented by formula (I), a preparation method thereof and an application thereof in the pharmaceutical field, wherein R1, R2, R3 and A are as defined in the description and claims.

公开(公告)号：US20240217966A1

公开(公告)日：2024-07-04

申请号：US18281848

申请日：2022-03-23

申请人： Shionogi & Co., Ltd.

发明人： Misato KITAMURA FUJIWARA ,  Shomitsu MAENO ,  Yuji NISHIURA

IPC分类号： C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  C07D405/14

CPC分类号： C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  C07D405/14

摘要： The present invention relates to a compound that has GLP-1 receptor agonist activity and is useful as a therapeutic or prophylactic agent for diseases associated with the GLP-1 receptor, or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition containing the compound or its pharmaceutically acceptable salt.
Provided is a compound represented by formula (I):






wherein A1 is C(R5) or the like, A2 is C(R6) or the like, A3 is C(R7) or the like, R5, R6, and R7 are each independently a hydrogen atom or the like, R1 is carboxy or the like, R2 is substituted or unsubstituted alkyl or the like, —X— is —O— or the like, the ring represented by:










is a ring represented by:










 and the like
wherein
R10 is each independently halogen or the like,
s is 0 or the like,
R13 is each independently a hydrogen atom or the like, and R3 is substituted or unsubstituted aromatic carbocyclyl or the like, or
a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240217949A1

公开(公告)日：2024-07-04

申请号：US18429297

申请日：2024-01-31

申请人： ZHUHAI UNITED LABORATORIES CO., LTD.

发明人： Peng LI ,  Xiaolin LI ,  Zhi LUO ,  Haiying HE ,  Guoping HU ,  Jian LI ,  Shuhui CHEN

IPC分类号： C07D401/12 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/444 ,  A61P27/04 ,  C07D213/73 ,  C07D401/04 ,  C07D401/06

CPC分类号： C07D401/12 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/444 ,  A61P27/04 ,  C07D213/73 ,  C07D401/04 ,  C07D401/06

摘要： Provided is an aldehyde binder, specifically, disclosed is a compound as represented by formula (II) or a pharmaceutically acceptable salt.

公开(公告)号：US12024519B2

公开(公告)日：2024-07-02

申请号：US17525010

申请日：2021-11-12

申请人： Shionogi & Co., Ltd.

发明人： Kouhei Nodu ,  Yusuke Tateno ,  Kengo Masuda ,  Yuji Nishiura ,  Yoshikazu Sasaki

IPC分类号： A61K31/438 ,  A61K31/444 ,  C07D471/10 ,  C07D471/20 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

CPC分类号： C07D471/20 ,  A61K31/438 ,  A61K31/444 ,  C07D471/10 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

摘要： The present invention provides the compound represented by the following formula (I):




wherein a moiety represented by formula:





is





or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

公开(公告)号：US20240208955A1

公开(公告)日：2024-06-27

申请号：US18280794

申请日：2022-03-07

申请人： RESEARCH TRIANGLE INSTITUTE

发明人： Chunyang JIN ,  Elaine GAY

IPC分类号： C07D413/14 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/444 ,  C07D413/12

CPC分类号： C07D413/14 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/444 ,  C07D413/12

摘要： Non-peptide, small molecule antagonists of the relaxin family peptide 3 receptor (RXPP3) that can inhibit relaxin-3 activity are described. The compounds can include a pyrrolidone or piperidone substituted with an aryl amide. Also described are methods of preparing the antagonists and methods of using the antagonists to treat diseases, disorders and conditions, such as obesity, alcoholism and other substance abuse and/or addiction-related conditions.

公开(公告)号：US12018402B2

公开(公告)日：2024-06-25

申请号：US16325856

申请日：2017-08-17

申请人： Quest Diagnostics Investments LLC

发明人： Michael J. McPhaul ,  Heather R. Sanders

IPC分类号： C40B30/04 ,  A61K31/03 ,  A61K31/48 ,  A61K31/567 ,  A61K31/4174 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/451 ,  A61K31/496 ,  A61K31/506 ,  C12Q1/6806 ,  C12Q1/6886

CPC分类号： C40B30/04 ,  A61K31/03 ,  A61K31/48 ,  A61K31/567 ,  A61K31/4174 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/451 ,  A61K31/496 ,  A61K31/506 ,  C12Q1/6806 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The present technology is related to methods for detecting genetic alterations underlying intracranial neoplasms such as pituitary adenomas, meningiomas, and craniopharyngiomas. The methods disclosed herein are useful in determining whether a patient harboring an intracranial tumor will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. Kits for use in practicing the methods are also provided.

公开(公告)号：US20240197703A1

公开(公告)日：2024-06-20

申请号：US18144737

申请日：2023-05-08

申请人： PFIZER INC.

发明人： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC分类号： A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

CPC分类号： A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

摘要： This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.